Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07322757

Outcomes-Based Health Program for Type 2 Diabetes

Type 2 diabetes is a growing health concern worldwide, influenced by genetic factors, overweight, metabolic syndrome, and insufficient physical activity. Good treatment and glycemic control can reduce or delay diabetes-related complications, which account for a significant and increasing share of healthcare costs in Finland. Much of this cost growth is due to complications resulting from inadequate diabetes care. Secondary prevention programs can therefore provide both health and economic benefits. Lifestyle interventions are one way to improve type 2 diabetes care and reduce complications.

This study aims to evaluate the impact of a digital lifestyle intervention combined with optimized care on treatment and outcomes among adults with type 2 diabetes at high risk for complications.

The intervention includes access to the BitHabit "Small Actions" application, which supports healthy lifestyle changes, and for participants with a body mass index (BMI) over 30, the Onnikka weight management application. The study will be conducted in North Savo, Finland, using a case-control design. Approximately 120 participants will receive the intervention and 50-100 will serve as controls. All participants will have their care plans reviewed and updated according to the Finnish Current Care Guidelines for Type 2 Diabetes. Control group participants will receive standard care, while the intervention group will receive standard care plus the digital tools. The study also includes the validation of the PAID (Problem Areas in Diabetes) questionnaire for use in Finland and in the Finnish language.

The study duration for each participant is 12 months. Data will be collected through physiological measurements, laboratory tests, questionnaires, and app usage logs. Measurements and questionnaires will be conducted at baseline and after 12 months. The analyses will describe the phenomenon, its prevalence, and associations between variables, as well as potential dependencies.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Type 2 Diabetes Diabetes Mellitus Diabetes Mellitus, Type 2 Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

35 year–74 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Wellbeing services county of North Savo, Nursing and Physician Services

Kuopio, Northern Savonia, Finland

Location status: Recruiting

Location contact

Sonja Soininen, MD, PhD

CONTACT

[email protected]

+358444611199

Sonja Soininen, MD, PhD

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Type 2 diabetes diagnosed
  • At least one of the following:
  • diagnosed coronary artery disease,
  • diagnosed periferal artery disease,
  • diagnosed heart failure,
  • diagnosed diabetic renal disease (GFR <60 OR uACR ≥ 3 for at least three months),
  • diagnosed diabetic retinopathy,
  • previous stroke,
  • diagnosed atrial fibrillation or atrial flutter,
  • age ≥ 55 years and at least two of the following conditions:
  • smoker
  • uses antihypertensive medication or systolic blood pressure >140 mmHg or diastolic blood pressure > 80 mmHg,
  • uses lipid lowering medication or LDL-cholesterol > 2.6 or
  • BMI > 25

Exclusion criteria

  • eGFR < 30
  • uACR > 200
  • BMI > 50
  • heart ejection fraction EF < 30
  • active cancer or less than five years from cancer treatment at enrollment
  • blindness in both eyes
  • severe psychotic depression
  • inability to utilize digital applications

Treatment and study plan

BitHabit digital application for behavioral lifestyle changes

Other

BitHabit digital application for behavioral lifestyle changes

Onnikka weight management digital application

Other

Onnikka weight management digital application

Primary outcomes

  1. Change from baseline in weight at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in weight at 12 months. Weight measurement is taken by study nurse both at baseline and at the end of the study.

  2. Change from baseline in BMI at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in BMI at 12 months. Weight and height measurement are taken by study nurse both at baseline and at the end of the study.

  3. Change from baseline in waist circumference at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in waist circumference at 12 months. Waist circumference is taken by study nurse both at baseline and at the end of the study.

  4. Change from baseline in Body Roundness Index at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in Body Roundness Index at 12 months. Weight, height, waist and hip circumference are taken by study nurse both at baseline and at the end of the study.

  5. Change from baseline in HbA1c at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in HbA1c at 12 months. HbA1c is a laboratory measurement describing glucose levels, taken both at baseline and at the end of the study.

  6. Change from baseline in serum lipid levels at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in serum lipid levels at 12 months. LDL, HDL and triglycerides are laboratory measurements taken both at baseline and at the end of the study.

  7. Change from baseline in smoking status at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in smoking status at 12 months. Smoking status is surveyed both at baseline and at the end of the study.

  8. Change from baseline in physical activity at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in physical activity at 12 months. Physical activity is surveyed both at baseline and at the end of the study.

  9. Change from baseline in dietary habits at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in dietary habits at 12 months. Dietary habits are surveyed both at baseline and at the end of the study.

  10. Change from baseline in blood pressure at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    Change from baseline in blood pressure at 12 months. Blood pressure measurement is taken by study nurse via Riva Rocci method both at baseline and at the end of the study.

  11. Self-reported changes from baseline in qualty of life measured by EQ-5D-5L at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    EQ-5D-5L is a standard health questionnaire assessing quality of life across five dimensios: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. EQ-5D-5L questionnaire is filled electronically at baseline and at the end of the study.

  12. Change from baseline in Problem Areas in Diabetes (PAID) scale at 12 months

    Time frame: From enrollment to the end of follow-up at 12 months

    PAID scale identifies emotional distress in diabetes, covering issues like worrying complications, goal setting, food, treatment, and social support, common problems including fear, anger, feeling overwhelmed and guilt.

Study contacts

Contact information is provided by the study sponsor or research team.

Elina Pimiä, MD

CONTACT

[email protected]

+358503222755

Sonja Soininen, MD, PhD

CONTACT

[email protected]

+358444611199

Sponsors and collaborators

Lead sponsor

Kuopio University Hospital

Other

Collaborators

  • Finnish Diabetes Association
  • University of Eastern Finland

Registry information

Official study title

Outcomes-Based Health Program for Improving Care and Outcomes in Patients With Type 2 Diabetes: A Real-World Implementation Study in Primary Care

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Jan 7, 2026
Registry last updated
Jan 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.